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ABSTRACT 
 
Context: Statin therapy has been associated with pancreatitis in observational studies. 
Although lipid guidelines recommend fibrate therapy to reduce pancreatitis risk in 
those with hypertriglyceridemia, fibrates may lead to the development of gallstones, a 
risk factor for pancreatitis.  
Objective: To investigate associations between statin and fibrate therapy, 
respectively, and incident pancreatitis in large randomized trials. 
Data Sources: We identified relevant trials in literature searches of MEDLINE, 
EMBASE and Web of Science (1 January 1994 for statin trials, 1 January 1972 for 
fibrate trials through 9 June 2012). Published pancreatitis data were tabulated where 
available (6 trials). Unpublished data were obtained from investigators (22 trials). 
Study Selection: We included randomized controlled cardiovascular end-point trials 
investigating effects of statin therapy and fibrate therapy, respectively. Studies with 
more than 1000 participants followed for over 1 year were included. 
Data Extraction: Trial-specific data described numbers of participants developing 
pancreatitis and change in triglycerides at 1 year. We calculated trial-specific risk 
ratios (RR) and combined these using random-effects model meta-analysis. Between-
study heterogeneity was assessed using the I2 statistic. 
Results: In 16 placebo- and standard care-controlled statin trials with 113,800 
participants conducted over a weighted mean (standard deviation) follow-up of 4.1 
(1.5) years, 309 developed pancreatitis (134 assigned statin, 175 assigned control), RR 
0.77 (95% confidence intervals [CI], 0.62-0.97; p=0.027; I2=0%). In 5 dose-
comparison statin trials with 39,614 participants conducted over 4.8 (1.7) years, 156 
developed pancreatitis (70 assigned intensive-dose statin, 86 assigned moderate-dose), 
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RR 0.82 (95% CI, 0.59-1.12; p=0.21; I2=0%). Combined results for all 21 statin trials 
provided RR 0.79 (95% CI, 0.65-0.95; p=0.011; I2=0%). In seven fibrate trials with 
40,162 participants conducted over 5.3 (0.5) years, 144 developed pancreatitis (84 
assigned fibrate therapy, 60 assigned placebo), RR 1.39 (95% CI 1.00-1.95; p=0.053; 
I2=0%). 
Conclusion: In a pooled analysis of randomized trial data, use of statin therapy was 
associated with a lower risk of pancreatitis. 
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INTRODUCTION 
 
Pancreatitis is a condition with a clinical spectrum ranging from a mild, self-limiting 
episode to a severe or fatal event. Numerous case-reports and pharmaco-
epidemiological studies have stated that statins may be associated with an increased 
incidence of pancreatitis(1-4) though few comprehensively considered confounding 
factors. Very few large randomized trials of statin therapy have published data on 
incident pancreatitis. Recently reported data from the Study of Heart and Renal 
Protection (SHARP), a trial comparing combination therapy of simvastatin and 
ezetimibe with placebo on cardiovascular events in patients with chronic kidney 
disease, demonstrated a reduction in pancreatitis cases in those on simvastatin and 
ezetimibe suggesting a possible protective effect (5). In addition, statins reduce bile 
cholesterol content (6) which may theoretically reduce the risk of developing 
gallstones, a risk factor for pancreatitis. 
 
Hypertriglyceridemia is the third most common cause of pancreatitis (7). Guidelines 
for lipid modifying therapies include advice to initiate triglyceride-lowering therapy, 
usually fibrates, in those with moderate and severe hypertriglyceridemia (above 400 
to 500mg/dL) (8;9). However, high quality evidence for this approach is lacking and 
only observational data exist (10;11). In addition, some evidence suggests that fibrates 
may be associated with an increased risk of pancreatitis among patients with lower 
triglyceride levels than the threshold triglyceride level identified in published 
guidelines (12). Fibrates increase bile cholesterol concentration and may increase the 
risk of gallstones (13;14). However, few large randomized placebo-controlled trials of 
fibrate therapy have published data on pancreatitis.  
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Associations of statin and fibrate medications with pancreatitis are therefore 
uncertain. We examined the associations between statin and fibrate therapy, 
respectively, and the incidence of pancreatitis by conducting a collaborative meta-
analysis of published and unpublished data from large randomized clinical trials. 
 
METHODS 
 
We gathered data from large randomized end-point trials primarily designed to assess 
the effects of statin therapy (including both placebo- and standard care-controlled 
trials plus intensive-dose vs. moderate-dose trials) and fibrate therapy, respectively, 
on cardiovascular events. Inclusion criteria were trials with 1000 or more participants 
exposed to randomized therapy with a minimum mean follow-up of one year as in 
previous large statin meta-analyses (15). This was based on the rationale that the large 
trials contained the vast majority of patient-years of follow-up and would be most 
likely to employ systematic collection of clinical endpoints and serious adverse 
events. We excluded trials conducted in patients with previous organ transplant or on 
hemodialysis, and trials comparing combination therapy to placebo. We searched 
MEDLINE, EMBASE and Web of Science databases with the terms statin, HMG 
CoA reductase inhibitor and fibrate, and also names of individual statins 
(atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, 
simvastatin) and fibrates (bezafibrate, ciprofibrate, clofibrate, fenofibrate, 
gemfibrozil) as title words and keywords, limited to studies defined as randomized 
controlled trials, to identify relevant studies performed in adult patients (initial search 
on October 28, 2011, search updated June 9, 2012) and published from January 1, 
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1972 (fibrate trials) or January 1 1994 (statin trials), until June 9, 2012 (Figure 1) 
without language restrictions. Reference lists for the studies identified in the literature 
search were also searched for additional studies. The Food and Drug Administration 
Agency website was also searched for trial reports containing relevant data. Abstracts, 
manuscripts and reports were reviewed independently by 2 readers (D.P. and P.W.) in 
an unblinded fashion. A third reviewer (N.S.) settled discrepancies. In the small 
number of trials where published data regarding incident pancreatitis and change in 
triglyceride levels were available, these data were tabulated. In the majority of trials 
where no relevant data were available, trial investigators were contacted with a 
request to provide the required information. After the full articles were reviewed and 
data were received from collaborators, 21 statin trials (5;16-36) (Table 1) and seven 
fibrate trials (Table 2) (12;37-43) were included in the analyses. As unpublished data 
were made available for both the Helsinki Heart Study (40) and its smaller ancillary 
study (44), conducted in similar groups of participants randomized to the same 
therapies over the same follow-up times, these results were combined in one overall 
study. 
 
Data Sources 
Published data for incident pancreatitis were available from 2 statin trials (5;22;36) 
and 4 fibrate trials (12;37-39;41). Unpublished data were collected from 19 statin 
trials (16-21;23-35) and 3 fibrate trials (40;42;43). To examine whether there was a 
relationship between the extent of triglyceride-lowering between active and control 
therapy arms in the trials and risk of pancreatitis, we collected data on average change 
in triglycerides at one year. A PRISMA checklist was provided to the journal at the 
time of manuscript submission (45). 
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Quality Assessment  
Two authors (D.P. and P.W.) used an established tool, the Jadad score, to 
independently evaluate the quality of each trial (46). The Jadad score is designed to 
assess trials with regard to method of randomization, whether the trial is double 
blinded and whether withdrawals / dropouts are described, thereby allowing a score of 
up to 5 points. A third reviewer (N.S.) was available to resolve any disagreement by 
consensus and discussion.  
 
End Points  
A patient was considered to have developed pancreatitis during the trial if this was 
recorded as a serious adverse event or adverse event. This information was identified 
using different approaches across the trials, namely (1) text word searches of adverse 
event reports, including self-reported data of hospitalization, for pancreatitis; (2) 
Medical Dictionary for Regulatory Activities (MedRa) event classification; (3) 
International Classification of Diseases (ICD) classifications ICD-10 (K85, K86.0, 
K86.1) or ICD-9 (577.0 and 577.1), according to the preference of each trial’s 
investigators. All reports of pancreatitis were included regardless of suggested 
etiology (information regarding alcohol intake was not available) or whether the 
condition was described as acute, chronic or neither, based on the rationale that such 
additional data may have been largely absent or variably reported across trials. 
 
Statistical Analysis 
To identify potential associations of lipid modifying therapies with the risk of 
developing pancreatitis, we calculated risk ratios (RR) as the ratio of cumulative 
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incidence and 95% CIs from the available data for all trial participants at baseline and 
those who developed pancreatitis during trial follow-up. Study-specific RRs were 
pooled using a random-effects model meta-analysis as the preferable approach to 
manage potential between-study heterogeneity that may have been introduced by the 
differing methods for identifying participants with incident pancreatitis available in 
the trials and different trial populations. Statistical heterogeneity across studies was 
quantified using both the χ2 (or Cochran Q statistic) and I2statistics, with p>0.10 
considered statistically non-significant. The I2 statistic is derived from the Q statistic 
([Q−df/Q]X100) and provides a measure of the proportion of the overall variation 
attributable to between-study heterogeneity (47). Placebo- and standard care-
controlled statin trials plus intensive-dose vs. moderate-dose statin trials, were 
analysed both separately (with comparison of analyses by fixed-effect inverse-
variance method) and in a combined analysis. In sensitivity analyses, only trials with 
previously published pancreatitis data were examined; and fixed-effects model meta-
analyses were also performed. We assessed the potential for publication bias through 
formal statistical testing, namely funnel plots and Egger tests. To evaluate the 
potential relationship between the associations of lipid modifying agents with incident 
pancreatitis and relative reductions in triglyceride levels achieved at one year on 
statins and fibrates respectively, random-effects meta-regression analyses were 
performed. All p values were 2-sided and p<0.05 was considered statistically 
significant for the meta-analyses and meta-regression analyses. Analyses were 
conducted using Stata version 10.1 (StataCorp, College Station, Texas). 
 
Funding 
This project was not supported by external funding. 
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RESULTS 
 
Statin therapy and pancreatitis 
Twenty-one randomized clinical trials of statin therapy, two with published data 
regarding incident pancreatitis and 19 with unpublished data, provided data on 
153,414 participants over a weighted mean (standard deviation [SD]) follow-up 
period of 4.3 (1.6) years. Baseline average triglyceride levels in the trials varied from 
118 to 187 mg/dL. Trials were of high quality with a median Jadad score of 5 (range 
3-5) and 100% agreement between reviewers.  
 
In 16 placebo- and standard care-controlled statin trials with 113,800 participants 
conducted over 4.1 (SD-1.5) years, 309 (0.27%) developed pancreatitis (134 assigned 
statin, 175 assigned control), RR 0.77 (95% CI, 0.62-0.97; p=0.027) (Table 1, Figure 
2). This represents a number needed to treat (NNT) of 1175 (95% CI 693-9195) over 
5 years. There was limited heterogeneity between statin trials for incident pancreatitis 
(χ2=9.11; I2=0%).  
 
In 5 dose-comparison statin trials with 39,614 participants conducted over 4.8 (SD- 
1.7) years, 156 (0.39%) developed pancreatitis (70 assigned intensive-dose statin, 86 
assigned moderate-dose), RR 0.82 (95% CI, 0.59-1.12; p=0.21) (Table 1, Figure 2). 
There was again limited heterogeneity between these trials for incident pancreatitis 
(χ2=1.29; I2=0%). 
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There was no evidence of statistical heterogeneity between the analyses of placebo-
controlled trials and intensive vs. moderate- statin dose trials (p=0.79 for interaction). 
 
In the combined dataset of 21 statin trials, 465 (0.30%) developed pancreatitis (204 of 
whom were assigned to statin therapy or intensive-dose statin therapy, 261 assigned to 
placebo, standard care or moderate-dose statin therapy respectively), RR 0.79 (95% 
CI, 0.65-0.95; p=0.011; χ2=10.48; I2=0%) (Table 1, Figure 2). This represents a NNT 
of 1187 (95% CI 731-4768) over 5 years. There was no evidence of publication bias 
(p=0.83; eFigure 1A). Meta-regression analysis found no relationship across the trials 
between risk of pancreatitis and reduction in triglyceride levels at one year though this 
analysis was of limited value given the limited statistical heterogeneity between trial-
specific RRs (p=0.23; eFigure 2A).  
 
Using a fixed-effects model approach produced identical results (RR 0.79, 95% CI 
0.65-0.95; p=0.011) to the random-effects model. In a sensitivity analysis of only the 
two trials with published data (22;36), 122 (0.37%) developed pancreatitis (52 of 
16,300 assigned to statin therapy or intensive-dose therapy, 70 of 16,300 assigned to 
placebo or moderate-dose statin therapy), RR 0.74 (95% CI 0.52-1.07; p=0.11; 
χ2=0.30; I2=0%).  
 
Fibrate therapy and pancreatitis 
Seven randomized clinical trials of fibrate therapy, four with published data and three 
with unpublished data regarding incident pancreatitis, provided data on 40,162 
participants over a weighted mean (SD) follow-up period of 5.3 (0.5) years. Baseline 
average triglyceride levels in the trials varied from 145 to 184 mg/dL. Trials were of 
11 
 
high quality with a median Jadad score of 5 (range 5-5) and 100% agreement between 
reviewers. During this time, 144 (0.36%) developed pancreatitis (84 assigned fibrate 
therapy, 60 assigned placebo), RR 1.39 (95% CI 1.00-1.95; p=0.053) (Table 2, 
Figure 3). This represents a number needed to harm of 935 (95% CI 388- greater than 
50,000) over 5 years. There was limited heterogeneity between trials for incident 
pancreatitis (χ2=4.48; I2=0%). Likewise, there was no evidence of publication bias 
(p=0.59; eFigure 1B). Meta-regression analysis found no relationship across the trials 
between risk of pancreatitis and reduction in triglyceride levels at one year across the 
trials (p=0.81; eFigure 2B) though this analysis was of limited value given the limited 
statistical heterogeneity between trial-specific RRs, and similar relative reductions in 
triglyceride levels achieved across the trials.  
 
Using a fixed-effects model approach produced identical results to the random-effects 
model (RR 1.39, 95% CI 1.00-1.95; p=0.053). In a sensitivity analysis of only the four 
trials with published data (12;37;39;41), 69 (0.26%) developed pancreatitis (44 of 
12,593 assigned to fibrate therapy, 25 of 14,252 assigned to placebo), RR 1.75 (95% 
CI 1.07-2.86; p=0.026; χ2=1.19; I2=0%).  
 
COMMENT 
 
This report of pooled randomized trial data demonstrates that use of statin therapy was 
associated with a reduction in the number of patients developing pancreatitis. Broadly 
similar results were obtained for both statin compared with placebo and for intensive-
dose statin therapy compared with moderate-dose therapy, in keeping with a dose-
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dependent association. However, we did not demonstrate an association between use 
of fibrate therapy and risk of pancreatitis.  
 
Previously published case-reports and observational pharmaco-epidemiological 
studies have demonstrated an association between statin therapy and increased risk of 
pancreatitis (1-4). However, such analyses are susceptible to bias by unmeasured 
confounders and to confounding by indication. The present analysis, however, 
indicates that statin therapy may be associated with a lower risk of pancreatitis 
overall. Though we cannot completely exclude the possibility that statin therapy may 
lead to very occasional idiosyncratic cases of pancreatitis, the randomized trial data 
appear reassuring. Unlike fibrates, statins are not known to increase the risk of 
developing gallstones (48). Studies showing associations between statin use and both 
a reduction in bile cholesterol and reduced risk of gallstones on statins suggest the 
possibility of a protective effect (6;49). Furthermore, studies conducted in animal 
models suggest the possibility that statin therapy may be associated with benefit for 
both acute pancreatitis and chronic pancreatitis (50-52).  
 
Major guidelines of lipid-modifying therapy such as the National Cholesterol 
Education Program, Third Report of the Expert Panel on Detection, Evaluation and 
Treatment of High Blood Cholesterol in Adults (NCEP ATP III) (8) and the National 
Institute for Health and Clinical Excellence (NICE), Type 2 Diabetes guideline (9), 
suggest that fibrate therapy should be prescribed for patients with moderately elevated 
triglyceride levels and higher (>500mg/dL and >400mg/dL respectively). This is 
based on the rationale that hypertriglyceridemia is a well-recognized cause for 
pancreatitis and that lowering triglycerides should therefore be clinically beneficial 
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(7). However, no convincing trial data exist to support the hypothesis that fibrate 
therapy is associated with prevention of pancreatitis for patients with 
hypertriglyceridemia. Participants in the Coronary Drug Project assigned to clofibrate 
had a 50% higher incidence of cholelithiasis or cholecystitis than those on placebo 
(13) and gallstones are a well-known cause of pancreatitis. In addition, it has been 
demonstrated in small clinical studies that both fenofibrate, a fibrate thought less 
likely to cause gallstones, and bezafibrate are associated with a higher cholesterol 
content of bile, thereby theoretically increasing the risk of developing gallstones 
(14;53). Following the Coronary Drug Project, other large fibrate trials did not find a 
significant increase in the incidence of gallbladder disease though the total number of 
cases was small (40;41;43). Our analysis did not demonstrate an association between 
fibrate therapy and the risk of pancreatitis though we may have lacked statistical 
power to show an increased risk in patients with slightly elevated triglycerides (the 
range at baseline in the trials we examined was 145-184 mg/dL). It remains possible, 
however, that fibrates might have a different net effect in patients with higher 
triglyceride levels. 
 
Although the present results for both statins and fibrates should be considered 
hypothesis-generating and while the number of cases of pancreatitis was small in this 
trial population at low risk of pancreatitis, it raises questions regarding the choice of 
lipid modifying agents in hypertriglyceridemic patients. In those with slightly elevated 
triglycerides, statin therapy appears better supported by the available data than 
fibrates for preventing pancreatitis. Lifestyle modifications also remain important to 
improve lipid profiles in such individuals. In those patients with severe 
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hypertriglyceridemia, a trial comparing fibrates and statins for preventing pancreatitis 
would be clinically valuable. 
  
Strengths of this meta-analysis include the following: first, the meta-analysis was 
conducted using data from randomized trials which avoids most of the potential bias 
of unmeasured confounders encountered in observational studies. Second we included 
data from almost all the relevant trials, both published and unpublished, thereby 
maximizing power and providing the best answer possible with existing data. 
Limitations include the following: first, pancreatitis was not a pre-specified endpoint 
in the trials which were primarily designed to assess the effect of lipid modifying 
therapy on cardiovascular events. However, limited statistical heterogeneity between 
trial results for statins and fibrates, respectively, plus evidence of a dose-dependent 
association for statins provides confidence in the findings. Second, the occurrence of 
pancreatitis was not recorded in a standardized way with resultant variation between 
trials. Therefore these results, especially for fibrate therapy where there were 
relatively few events which were dominated by two trials (12;43), should be 
interpreted with caution. Third, as it was felt unlikely that the cause of pancreatitis 
would have been consistently recorded in an accurate way across trials, we were 
unable to examine specific causes such as gallstones or alcohol. Data on alcohol use 
was not available. Likewise, we were unable to separate reports of pancreatitis into 
acute and chronic cases. However, given that the majority of trials used the presence 
of hepatobiliary disease as exclusion criteria, it is highly likely that the majority of 
cases included in this report represent de novo acute pancreatitis. This is supported by 
evidence from SHARP (5). Fourth, we did not have access to individual participant 
data which may have reduced our ability to identify any relationship of therapy with 
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the extent of triglyceride lowering. And fifth, as the trials tended to exclude 
participants with marked hypertriglyceridemia, these findings may not necessarily be 
generalizable to that specific group of patients. 
 
In summary, pooled analyses of randomized trial data suggest that statin therapy is 
associated with a reduction in the risk of pancreatitis in patients with normal or mildly 
elevated triglyceride levels. 
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FIGURE LEGENDS 
 
Figure 1. Flow Diagram of the Literature Search 
 
Figure 2. Meta-analysis of incident pancreatitis in twenty-one large statin trials 
Footnote: for abbreviations see Table 1; data marker size indicates relative weight of 
the study  
 
Figure 3. Meta-analysis of incident pancreatitis in seven large fibrate trials 
Footnote: for abbreviations see Table 2; data marker size indicates relative weight of 
the study 
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Table 1. Baseline data from twenty large statin trials 
 
Trial Year 
published 
N on 
statin  
N on 
control  
Treatment (active 
/ control) 
Follow 
up 
(years) 
Trial population (triglyceride 
inclusion criteria) 
Age 
(years) 
Baseline 
triglycerides 
(mg/dL) 
% difference in 
triglycerides 
between treatment 
and control arms at 
1 year 
PLACEBO- AND STANDARD CARE-CONTROLLED TRIALS 
4S (16) 1994 2223  2221 S10-40mg / 
placebo 
5.4* Angina or previous MI 
(triglycerides ≤222mg/dL) 
- 134 (45) 18 
WOSCOPS (17) 1995 3302 3293 P40mg / placebo 4.9 Male, hypercholesterolemia, no 
history of MI (-) 
55 164 (69) 15 
CARE (18) 1996 2081 2078 P40mg / placebo 5.0* MI in previous 3 to 20 months 
(triglycerides <350mg/dL) 
59 156 (61) 14∫ 
AFCAPS TexCAPS (19) 1998 3304  3301 L20-40mg / 
placebo 
5.2 Average cholesterol levels, no 
CVD (triglycerides ≤400mg/dL) 
58 181 (75) 14 
LIPID (20) 1998 4512 4502 P40mg / placebo 6.1 hospitalization for unstable 
angina or previous MI 
(triglycerides <445mg/dL) 
62* 140* 11∫ 
GISSI-Prev. (21) 2000 2138 2133 P20mg / standard 
care 
2.0* Recent MI (-) - 166 (89) -4 
Heart Protection Study 
(5;22) 
2002 10269 10267 S40mg / placebo 5.4 CVD or diabetes (-) 65 187 (125) 19 
PROSPER (23) 2002 2891 2913 P40mg / placebo 3.3 Age 70-82 years with CVD or 
risk factors (triglycerides 
<534mg/dL) 
75 138 (62) 17 
GREACE (24) 2002 800 800 A to achieve LDLc 
<100mg/dL / 
standard care 
3.0 CHD (triglyceride <400mg/dL) 59 181 28 
ASCOT-LLA (25) 2003 5168 5137 A10mg / placebo 3.3* Hypertension, no CHD 
(triglyceride ≤400mg/dL) 
63 147 (80) 23 
CARDS (26) 2004 1428 1410 A10mg / placebo 3.9* Type 2 diabetes mellitus, no 
CVD (triglyceride ≤603mg/dL) 
62 173 (97) 21 
ASPEN (27) 2006 1211 1199 A10mg / placebo 4.0 DM (triglyceride ≤600mg/dL) 61 146* 14‡ 
MEGA (28) 2006 3866 3966 P10-20mg / no 5.3 Hypercholesterolemia, no 58 148 (83) 6 
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treatment previous CHD or stroke (-) 
CORONA (29) 2007 2514 2497 R10mg / placebo 2.7* Systolic heart failure (-) 73 178 (114) 24** 
JUPITER (30) 2008 8901 8901 R20mg / placebo 1.9* No CVD, no diabetes, hsCRP 
≥2.0mg/L (triglycerides 
<500mg/dL) 
66* 118 (86-
169)* 
17 
GISSI-HF (31) 2008 2285 2289 R10mg / placebo 
 
3.9* Chronic heart failure (-)  68 - - 
INTENSIVE VS. MODERATE DOSE TRIALS 
PROVE-IT TIMI 22 (32) 2004 2099 2063 P40mg / A80mg 2.0 Recent hospitalization for ACS  
(-) 
58 156* 21* 
A to Z (33) 2004 2265 2234 Placebo – S20mg / 
S40-80mg 
2.0* Recent hospitalization for ACS  
(-) 
61* 149 (116-
199)* 
6 
TNT (34) 2005 4995 5006 A80mg / A10mg 4.9* Stable CHD (triglyceride 
≤600mg/dL) 
61 151 (71) - 
IDEAL (35) 2005 4439 4449 A80mg / S20-40mg 4.8* Previous MI (triglyceride 
≤600mg/dL) 
62 149 23 
SEARCH (5;36) 2010 6031 6033 S80mg / S20mg 6.7 Previous MI (-) 64 169 (107) 9 
TOTAL - 76722 76692  4.3 
(1.6) 
- - - - 
 
Data presented as mean or mean (SD) unless otherwise indicated; * median or median (interquartile range); ∫ average difference over5 years; ‡ difference at end of trial; ** 
difference at 3 months; (-) no triglyceride inclusion or exclusion criteria specified for trial 
 
Abbreviations: Scandinavian Simvastatin Survival Study (4S), West of Scotland Coronary Prevention Study (WOSCOPS), Air Force/Texas Coronary Atherosclerosis 
Prevention Study (AFCAPS TexCAPS), Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID), Gruppo Italiano per lo Studio della Sopravvivenza 
nell'Insufficienza cardiaca (GISSI) Prevenzione (Prev), Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial, Greek Atorvastatin and Coronary Heart 
Disease Evaluation (GREACE) study, Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA), Collaborative Atorvastatin Diabetes Study 
(CARDS), Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT TIMI 22) study, Aggrastat to Zocor (A to Z) study, Treating to New Targets (TNT) 
study, Incremental Decrease in Events through Aggressive Lipid Lowering (IDEAL) study, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-
Insulin-Dependent Diabetes Mellitus (ASPEN), Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group (MEGA), Controlled 
Rosuvastatin Multinational Trial in Heart Failure (CORONA), JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), 
GISSI-Heart Failure, SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine); S (simvastatin); P (pravastatin); L (lovastatin); A 
(atorvastatin); R (rosuvastatin); MI (myocardial infarction); CVD (cardiovascular disease); CHD (coronary heart disease); ACS (acute coronary syndrome); DM (diabetes 
mellitus) 
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Table 2. Baseline data from trials comparing fibrate therapy to placebo 
 
Trial Year 
published 
N on fibrate N on 
control 
Treatment 
(active / control) 
Follow 
up 
(years) 
Trial population 
(triglyceride inclusion 
criteria) 
Age 
(year
s) 
Baseline 
triglycerides 
(mg/dL) 
% difference 
in 
triglycerides 
at 1 year 
Coronary Drug 
Project (37;38)† 
1975 1103 2789 Clofibrate / 
placebo 
6.2 Male, previous MI (-) - 184 25 
WHO Co-operative  
Trial (39)†∫ 
1978 5331 5296 Clofibrate / 
placebo 
5.3 Male, upper third of 
cholesterol (-) 
46 - - 
Helsinki Heart 
Study** (40;44) 
1987 2362 2347 Gemfibrozil / 
placebo 
5.0 Male, No CHD or possible 
symptoms of CHD (-)  
47 177 (119) 35 
VA-HIT† (41) 1999 1264 1267 Gemfibrozil / 
placebo 
5.1* Male, CHD (triglyceride 
≤300mg/dL) 
64 161 (68) 31 
BIP (42) 2000 1548 1542 Bezafibrate / 
placebo 
6.2 Previous MI or stable angina 
(triglyceride ≤300mg/dL) 
60 145 (51) 21‡ 
FIELD (12) 2005 4895 4900 Fenofibrate / 
placebo 
5.0* DM, not on statin 
(triglyceride 89-445mg/dL) 
62 174 (78) 30 
ACCORD Lipid 
(43) 
2010 2765 2753 Simvastatin + 
fenofibrate / 
simvastatin + 
placebo 
4.7 DM, CVD or risk factors 
(triglycerides <750mg/dL on 
no lipid lowering therapy; 
<400mg/dL on therapy) 
62 162 (113-
229)* 
20 
TOTAL - 19268  20894 - 5.3 (0.5) - - - - 
 
Data presented as mean or mean (SD) unless otherwise indicated; * median or median (interquartile range); † only fatal cases of pancreatitis available; ** includes 
cases from both the Helsinki Heart Study and its ancillary study (age, baseline triglycerides and % difference in triglycerides are weighted means); ∫ includes cases 
during the trial and during 1st year after the trial; ‡ average difference during trial; (-) no triglyceride inclusion or exclusion criteria specified for trial 
 
Abbreviations: VA-HIT (Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Cholesterol Intervention Trial), BIP (Bezafibrate Infarction 
Prevention), FIELD (Fenofibrate Intervention and Event Lowering in Diabetes), ACCORD (Action to Control Cardiovascular Risk in Diabetes), MI (myocardial 
infarction), CHD (coronary heart disease), DM (diabetes mellitus), CVD (cardiovascular disease)
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